Loading page
Loading page
Loading substance route
Effects vary widely by individual, dose, and context.
The physical effects of AMT can be broken down into six components all of which progressively intensify proportional to dosage.
In comparison to more traditional psychedelics such as LSD, DMT and Psilocin, the AMT head space is described as not nearly as deep, insightful or profound.
The visual geometry that is present throughout this trip can be described as more similar in appearance to that of psilocin and 2C-E than LSD. At lower levels, they appear to be bland and simplistic but become equal in terms of intricacy and depth to that of any of the classical psychedelics. They can be comprehensively described as structured in their organization, organic in geometric style, intricate in complexity, large in size, fast and smooth in motion, colourful in scheme, glossy in colour, blurred in their edges and rounded in their corners. They have a 'natural' feel to them and at higher dosages are significantly more likely to result in states of Level 7B visual geometry over Level 7A.
At high dosages AMT can produce a full range of high level hallucinatory states in a fashion that is more consistent and reproducible than that of many other commonly used psychedelics.
The auditory effects of AMT are common in their occurrence and exhibit a full range of effects.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
AMT is generally considered to have low psychological addiction potential and is not habit-forming, with the desire to use typically decreasing with repeated experiences. Compulsive use is rarely reported, and users tend to be self-regulating.
AMT is not considered physically addicting. Withdrawal effects following discontinuation have not been reported.
Deaths have been reported in association with high doses or concomitant use of other drugs. Verified fatalities include a 22-year-old man in Florida and a British teenager, both of whom died after consuming approximately 1 gram of aMT. Twenty-two deaths were linked to aMT in England and Wales between 2012 and 2015 when it was available as a legal high. Hospitalizations have been reported after high-dose (over 60 mg oral) ingestion.
Acute cardiovascular effects including elevated heart rate, increased blood pressure, and abnormal heartbeat occur during intoxication; these effects become more pronounced at higher doses and can be life-threatening in cases of overdose.
Potential for serotonergic neurotoxicity has been suggested based on the structurally related compound alpha-ethyltryptamine (aET), which is a known serotonergic neurotoxin; direct evidence for aMT neurotoxicity in humans has not been established, but caution is warranted at high dosages or with repeated long-term use.
Temperature regulation suppression occurs during intoxication, with hyperthermia being a potentially life-threatening side effect at higher doses.
Extreme confusion and depersonalization have been reported at high doses. Neurologic side effects include agitation, restlessness, and confusion. True psychotic episodes are not commonly documented, but high doses can produce significantly disorienting mental states.
Alpha-methyltryptamine appears to have first been described in the scientific literature around 1929, though it remained relatively unstudied until the late 1950s. More intensive research on AMT began in the late 1950s and early 1960s, conducted alongside its close structural relative…
Not under international control (as of 2014)
Controlled as an analogue of 5-MeO-AMT, which is a Schedule 9 prohibited substance under the Poisons Standard. Possession, production, and sale are illegal. Reportedly listed on Schedule 8 of the Australian Customs import list since 2001.
Not mentioned in the Controlled Drugs and Substances Act. May still be subject to analogue provisions if sold for human consumption.
Placed on List B of controlled substances by the Danish Minister for the Interior and Health in 2010.
Listed in Anlage I (Schedule I) of the Betäubungsmittelgesetz (Narcotics Act) since January 31, 1993. Manufacturing, possession, import, export, purchase, sale, and dispensing without license are prohibited.
Placed on the Schedule C list of controlled substances in 2013.
Classified as a Schedule I controlled substance under Latvian drug legislation.
AMT and certain derivatives have been controlled substances since June 4, 2012. Possession, production, and sale are illegal.
Listed on the Decree on Classification of Illicit Drugs since 2013.
Classified as a health hazard under Lagen om förbud mot vissa hälsofarliga varor (Act on the Prohibition of Certain Goods Dangerous to Health) since March 1, 2005 via regulation SFS 2005:26. Sale and possession are illegal.
Made illegal on January 7, 2015 as a Class A drug under the Misuse of Drugs Act 1971 following an Advisory Council on the Misuse of Drugs recommendation to update the tryptamine catch-all clause. Previously uncontrolled because its alkyl substitution occurs on the alpha carbon rather than the nitrogen position.
Controlled under the Neue-Psychoaktive-Substanzen-Gesetz (New Psychoactive Substances Act). Possession, production, and sale are prohibited.
Classified as a controlled substance as of October 2015. Production, sale, import, and export are prohibited.
Classified as a controlled drug under Finnish national drug legislation.
Prohibited under Law 4139/2013. Became a controlled substance on February 18, 2003. Possession, production, and sale are illegal.
Made illegal on April 17, 2005. Possession, production, and sale are prohibited.
Controlled as a tryptamine derivative since 2012, listed on the 1st list of Narcotic Drugs and Psychotropic Substances. Medical use is prohibited.
Placed on the List of Hazardous Substances in Annex, § 2 in 2013.
Not specifically controlled under Spanish drug legislation as of available sources, though some references cite control under general prohibition laws.
Specifically named as a controlled substance alongside AET under Verzeichnis D (Schedule D) of Swiss controlled substances legislation.
Temporarily placed in Schedule I on April 4, 2003 under emergency scheduling procedures, then permanently scheduled on September 29, 2004. Classified as a hallucinogen with high abuse potential and no accepted medical use. Also listed as a dangerous drug in Arizona since April 2014 and Schedule I in Illinois.
24 sources cited
